Global Ophthalmol Drugs Market Top Leading Players with Strategies and Forecast 2022-2028

The global Ophthalmol drugs market is anticipated to grow at a significant CAGR of 5.5% during the forecast period (2022-2028). The global Ophthalmol drugs market is growing due to the rising prevalence of eye-related disorders, rising research and development activities related to the development of novel drugs, and increasing focus on developing combination therapies globally. According to a survey conducted by World Health Organization in October 2021, around 2.2 billion people have distance or near vision impairment. Out of these 2.2 billion vision impairment patients, glaucoma accounts for 7 million patients, and cataract accounts for 94 million patients globally. The rising prevalence of eye diseases is increasing the demand for Ophthalmol drugs, globally. Additionally, geriatric and diabetic patients are mostly diagnosed with glaucoma, cataracts, macular degeneration, and diabetic retinopathy. Thus, the rising population of geriatric and diabetic patients is also boosting the demand for Ophthalmol drugs.

The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and launches, to stay competitive in the market. For instance-

• In January 2022, Sun Pharmaceutical Industries Ltd. announced its launch of a dry eye treatment product in Canada.
• In December 2021, IACTA Pharmaceuticals, Inc. announced their strategic collaboration with TALLC Inc. to employ novel drug delivery technology in new ophthalmic therapeutic.
• In October 2021, US Food and Drug Administration approved VUITY 1.25%, the first and only eye drop to treat presbyopia commonly known as the age-related blurry near vision in adults. This drug was launched by AbbVie Inc.
• In August 2021, DelSiTech Ltd. announced its exclusive collaboration with VISUS THERAPEUTICS for the development of long-acting therapies in ophthalmology.
• In September 2020, Micro Labs USA, Inc. announced the launch of two products Dorzolamide 2% and Dorzolamide-Timolol 22.3-6.8 mg/mL for the treatment of glaucoma in the US market.
• In June 2020, Otsuka Pharmaceutical Co., Ltd. and Senju Pharmaceutical Co., Ltd. announced their collaboration for the launch of the new drug AILAMIDE in Japan for the treatment of glaucoma and ocular hypertension.

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Drug Class
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Bausch & Lomb Inc., Novartis AG, Pfizer Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., and Johnson & Johnson, Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Ophthalmol Drugs Market Report by Segment

By Type

• Prescription Drugs
• Over-the-counter-Drugs

By Drug Class

• Anti-Glaucoma Drug
• Dry Eye Drug
• Ophthalmic Anti-allergy/Inflammatory
• Retinal Drug
• Anti-infective Drugs
• Other Drugs

Global Ophthalmol Drugs Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa